The Women’s Heart Health Expansion Act of 2026 reauthorizes and expands the WISEWOMAN program to improve cardiovascular screenings and preventive care for high-risk women while mandating a GAO study on program effectiveness.
Angela Alsobrooks
Senator
MD
The Women’s Heart Health Expansion Act of 2026 reauthorizes and expands the CDC’s WISEWOMAN program to provide critical cardiovascular screenings and preventive health services for high-risk women. With $250 million in authorized funding through 2031, the bill aims to improve health outcomes related to blood pressure, cholesterol, and diabetes. Additionally, it mandates a GAO study to evaluate the program's reach, cost-effectiveness, and potential barriers to care.
Women’s Heart Health Expansion Act Allocates $250 Million for Screenings: New Preventive Care Rollout Starts in 2027
The Women’s Heart Health Expansion Act of 2026 reauthorizes the WISEWOMAN program, a federal initiative designed to catch heart disease before it becomes a crisis. By authorizing $250 million for fiscal years 2027 through 2031, the bill allows the CDC to hand out supplemental grants to clinics already providing breast and cervical cancer screenings. The goal is to turn a standard check-up into a one-stop shop for preventive health, adding screenings for blood pressure, cholesterol, and obesity into the mix. For a busy woman juggling a job and family, this means fewer separate appointments and a clearer picture of her overall health risks during a single visit.
One-Stop Health Shop
Under Section 2, the bill expands what your local clinic can do with federal grant money. Instead of just checking for cancer, providers can now use these funds to monitor chronic conditions like diabetes and high blood pressure. If a screening turns up a red flag, the law requires clinics to provide medical treatment referrals and follow-up services. This isn't just about handing someone a pamphlet; it’s about ensuring that if a retail worker or a teacher finds out they have high cholesterol, there is a specific plan and a professional to guide them toward treatment. The bill specifically targets women who are already eligible for cancer screenings or those deemed "high-risk" by the Secretary of Health and Human Services, ensuring the money goes where it is needed most.
Checking the Receipts
To make sure this $250 million investment actually moves the needle on public health, Section 3 mandates a deep dive by the Government Accountability Office (GAO). By September 30, 2027, the GAO must report back to Congress on how many people are actually using the program and whether it is truly cost-effective. They are tasked with looking at real-world outcomes—like whether blood pressure levels are actually dropping across the population—and identifying any barriers that keep women from accessing these screenings. This built-in accountability check is designed to spot bottlenecks in the system, ensuring that bureaucratic hurdles don't get in the way of a patient getting their heart checked.